Researchers at Tufts University Report New Data on Clinical Therapeutics (Generic Drugs and the Struggle To Compete: the Role of Skinny Labels).

A report from Tufts University discusses the use of "skinny labels" in the generic drug industry as a tool to expedite entry into the market when the first patent for a brand's drug compound expires. The article reviews the law on this marketing pathway for generic competitors and examines the limitations on its use. It concludes that as long as generic manufacturers follow the essential skinny-label rules, they will not be found guilty of induced or contributory infringement. The research emphasizes the importance of generic drugs in providing broad access to clinical therapeutic agents and highlights the role of skinny labels in facilitating competition in the marketplace. [Extracted from the article]